Related Experiment Video

Updated: Aug 9, 2026

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
09:12

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Published on: January 30, 2014

The LPS receptor (CD14) links innate immunity with Alzheimer's disease

K Fassbender1, S Walter, S Kühl

  • 1Department of Neurology, University of Goettingen, 37075 Goettingen, FRG. klaus.fassbender@med.uni-goettingen.de

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|November 5, 2003
PubMed

Insights

The innate immunity receptor CD14 interacts with Alzheimer

Area of Science:

  • Neuroimmunology
  • Innate Immunity
  • Neurodegenerative Diseases

Background:

  • The innate immune system rapidly responds to pathogens via microbe-detecting receptors like CD14.
  • Alzheimer's disease is a severe neurodegenerative disorder characterized by dementia.

Purpose of the Study:

  • To investigate the potential link between the innate immunity receptor CD14 and Alzheimer's disease.
  • To explore the role of CD14 in the neuroinflammatory response to amyloid peptide.

Main Methods:

  • Examined the interaction between CD14 and Alzheimer amyloid peptide fibrils.
  • Utilized CD14 neutralization antibodies and genetic deficiency models.
  • Assessed microglial activation and toxicity in response to amyloid peptide.
  • Analyzed microglial CD14 expression in Alzheimer's disease animal models.

Main Results:

  • CD14 was found to interact with Alzheimer amyloid peptide fibrils.
  • Neutralization or genetic deficiency of CD14 significantly reduced amyloid peptide-induced microglial activation and toxicity.
  • Microglial expression of CD14 was notably enhanced in animal models of Alzheimer's disease.

Conclusions:

  • CD14 plays a significant role in the neuroinflammatory response to amyloid peptide in Alzheimer's disease.
  • Targeting CD14 presents a potential therapeutic strategy for Alzheimer's disease.
  • Innate immunity research offers promising avenues for advancing Alzheimer's disease understanding and treatment.

More Related Videos

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...